Yr Athro John Ingram

(e/fe)

MA MSc DM(Oxon) FRCP(Derm) FAcadMEd

2026

• Wainman, H. E. and Ingram, J. R. 2026. Secondary care management of patients with hidradenitis suppurativa in the United Kingdom and Ireland: a survey of current practice. Clinical and Experimental Dermatology 51 (8), pp.1433-1441. (10.1093/ced/llag132)
• Simmonds, F. et al., 2026. Challenging outdated dogma: management of hidradenitis suppurativa symptoms and inflammatory burden should precede obesity advice [Letter]. British Journal of Dermatology ljag344. (10.1093/bjd/ljag344)
• Jemec, G. B. E. et al., 2026. European S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment. Journal of the European Academy of Dermatology and Venereology (10.1111/jdv.70638)
• Garg, A. et al., 2026. 74634 Increasing Hidradenitis Suppurativa Prevalence Over Time: Pooled Estimates Across Multiple United States National Claims Databases, 2018 to 2024 [Abstract]. Journal of The American Academy of Dermatology 95 (1), pp.AB267-AB267. (10.1016/j.jaad.2026.04.1078)
• Ingram, J. R. et al. 2026. Real-world treatment journey and unmet needs of people with hidradenitis suppurativa: Insights from social media research in China [Conference Absrtact]. Journal of The American Academy of Dermatology 95 (1), pp.AB376-AB376. (10.1016/j.jaad.2026.04.1501)
• Marzano, A. V. et al., 2026. Criteria for hidradenitis suppurativa competence centers. Dermatology and Therapy 16 , pp.3445-34. (10.1007/s13555-026-01783-1)
• Varambally, M. et al., 2026. Clinician-reported severity scores for HS [Conference Abstract]. Journal of The American Academy of Dermatology 95 (1) AB113. (10.1016/j.jaad.2026.04.461)
• Wainman, H. E. et al., 2026. Patient and healthcare professionals’ perspectives on pain management in hidradenitis suppurativa: a quantitative and qualitative study. British Journal of Dermatology (10.1093/bjd/ljag300)
• Prinsen, C. A. C. et al., 2026. Standardizing outcome measurement in Dermatology: the C3 manual and checklist for the development of core outcome sets. British Journal of Dermatology ljag281. (10.1093/bjd/ljag281)
• Wainman, H. E. , Goncalves, R. B. and Ingram, J. R. 2026. UK and Ireland residents’ hidradenitis suppurativa training: a cross-sectional survey [Letter]. Clinical and Experimental Dermatology (10.1093/ced/llag291)
• Ingram, J. R. and Garg, A. 2026. Introducing the investigator global assessment of hidradenitis suppurativa (I-GLASS) instrument. British Journal of Dermatology 194 (6), pp.1151-1153. ljag083. (10.1093/bjd/ljag083)
• Johns, J. et al. 2026. The Dermatology Life Quality Index (DLQI) in 70 guidelines and 58 registries of 55 countries: a systematic review [Conference Abstract]. British Journal of Dermatology 195 (Supp_1) ljag086.618. (10.1093/bjd/ljag086.618)
• Lim, A. X. H. et al., 2026. The Dermatology Life Quality Index in 70 guidelines and 38 registries: a systematic review involving 55 countries: the International Standard of Care in Dermatology [Conference Abstract]. British Journal of Dermatology 195 (Supp_1) ljag151.090. (10.1093/bjd/ljag151.090)
• Shah, R. et al. 2026. Family members and partners of people with autism experience a major impact on their quality of life as measured by the Family Reported Outcome Measure [Conference Abstract]. British Journal of Dermatology 195 (Supp_1) ljag086.662. (10.1093/bjd/ljag086.662)
• Shah, R. et al. 2026. Embedding patient and public involvement and engagement in clinical research: insights from the Family Reported Outcome Measure (FROM-16) [Conference Abstract]. British Journal of Dermatology 195 (Supp_1) ljag086.676. (10.1093/bjd/ljag086.676)
• Wainman, H. et al., 2026. Patient and healthcare professionals’ perspectives on pain management in hidradenitis suppurativa: a quantitative and qualitative study [Conference Abstract]. British Journal of Dermatology 195 (Supp_1) ljag086.617. (10.1093/bjd/ljag086.617)
• Chivardi, C. et al., 2026. Healthcare resource use, costs and health-related quality of life in the UK–Irish Atopic eczema Systemic Therapy Register (A-STAR): a pilot study. Skin Health and Disease vzag042. (10.1093/skinhd/vzag042)
• Bouazzi, D. et al., 2026. Evaluating the diagnostic accuracy of a screening questionnaire for detecting hidradenitis suppurativa: a pooled analysis of accuracy measures from the global hidradenitis suppurativa atlas (GHiSA) study. British Journal of Dermatology 194 (5), pp.869-878. (10.1093/bjd/ljag005)
• Ingram, J. R. 2026. Treat-to-target: optimising outcomes for hidradenitis suppurativa. British Journal of Dermatology 194 (5), pp.946-948. (10.1093/bjd/ljag041)
• Shah, R. et al., 2026. Beyond the burden: Measuring the quality of life impact of Parkinson's on family members/partners using FROM-16. Journal of Parkinson's Disease 16 (3), pp.518-528. (10.1177/1877718x261428288)
• Chernyshov, P. V. et al., 2026. Position statement of the EADV task forces with external experts on quality of life measurement in hidradenitis suppurativa: an update. International Journal of Dermatology (10.1111/ijd.70443)
• Nikolakis, G. et al., 2026. Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics. Journal of the European Academy of Dermatology and Venereology 40 (4), pp.658-669. (10.1111/jdv.70118)
• Varambally, M. et al., 2026. Clinician‐reported severity scores for hidradenitis suppurativa: A systematic review and meta‐analysis [Letter]. Journal of the European Academy of Dermatology and Venereology (10.1111/jdv.70477)
• McGrath, B. M. et al., 2026. Exploring the impact of fatigue and sleep disturbance in hidradenitis suppurativa: perspectives from patients and healthcare professionals. Acta Dermato-Venereologica 106 (10.2340/actadv.v106.adv-2025-0179)
• Martorell, A. et al., 2026. Defining moderate disease and progression in hidradenitis suppurativa: an expert framework to unlock the window of opportunity for prompt treatment. American Journal of Clinical Dermatology 27 , pp.217-226. (10.1007/s40257-026-01011-8)
• Sayed, C. J. et al., 2026. Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension. Journal of The American Academy of Dermatology 94 (3), pp.867-878. (10.1016/j.jaad.2025.11.031)
• Tarafdar, N. et al., 2026. Hidradenitis suppurativa patient-reported outcome measures. JAMA Dermatology 162 (3), pp.264-270. (10.1001/jamadermatol.2025.5644)
• Meldrum, E. and Ingram, J. R. 2026. Targeting neutrophil function as therapy for hidradenitis suppurativa. International Journal of Molecular Sciences 27 (4) 2076. (10.3390/ijms27042076)
• Garg, A. et al., 2026. Standardization of lesion classification and assessment by investigators in clinical trials for hidradenitis suppurativa. JAMA Dermatology 162 (1), pp.72-79. (10.1001/jamadermatol.2025.4652)
• Holgersen, N. et al., 2026. Impact of psychiatric disease and treatment on biologic drug survival in patients with hidradenitis suppurativa. Journal of The American Academy of Dermatology 94 (1), pp.325-328. (10.1016/j.jaad.2025.09.037)
• Nikolakis, G. et al., 2026. Delphi consensus: First-line use of biologics and small molecules in hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology (10.1111/jdv.70264)
• Thestrup Hansen, S. et al., 2026. Experiences of drainage and associated impacts: A qualitative study among patients with hidradenitis suppurativa. JEADV Clinical Practice (10.1002/jvc2.70274)

2025

• Ingram, J. R. et al. 2025. Bimekizumab pain outcomes in patients with hidradenitis suppurativa: pooled 48-week results from BE HEARD I&II phase 3 randomized clinical trials. Pain and Therapy 14 , pp.1861-1878. (10.1007/s40122-025-00779-7)
• Ingram, J. R. et al. 2025. The Hidradenitis suppurativa symptom and impact diary: development and psychometric evaluation of a novel set of patient reported outcomes for hidradenitis suppurativa. British Journal of Dermatology 193 (6), pp.1155-1164. (10.1093/bjd/ljaf307)
• Shah, R. et al., 2025. HSD33 differential impact of Type 1 and Type 2 diabetes on families: a UK cross-sectional study using FROM-16 [Abstract]. Value in Health 28 (12 S1), pp.S380. (10.1016/j.jval.2025.09.1694)
• Thorlacius, L. et al., 2025. The HIdradenitis suppurativa DrainagE (HIDE) Scale: development and content validation of patient reported outcome measure [Research Letter]. British Journal of Dermatology 193 (6), pp.1242-1244. (10.1093/bjd/ljaf317)
• Vyas, J. et al. 2025. A systematic review of the use of the Dermatology Life Quality Index (DLQI) in routine clinical practice: evidence from 287 articles across 56 countries. Clinical and Experimental Dermatology 50 (12), pp.2456-2465. (10.1093/ced/llaf343)
• Westerkam, L. L. et al., 2025. Establishment of standardized definitions and a core set of outcome characteristics following hidradenitis suppurativa surgery developed by an expert Delphi consensus. Journal of The American Academy of Dermatology 93 (6), pp.1499-1508. (10.1016/j.jaad.2025.08.041)
• Wainman, H. E. et al., 2025. Management of hidradenitis suppurativa in UK primary care: cross-sectional survey. British Journal of General Practice Open 9 (4) BJGPO.2025.0060. (10.3399/BJGPO.2025.0060)
• Bouazzi, D. et al., 2025. Prevalence of hidradenitis suppurativa. JAMA Dermatology 161 (10), pp.1022-1028. (10.1001/jamadermatol.2025.2373)
• Bechara, F. G. et al., 2025. Towards a paradigm shift in delivering hidradenitis suppurativa care: a narrative review. Dermatology and Therapy 15 , pp.2317-2333. (10.1007/s13555-025-01462-7)
• Wainman, H. E. et al., 2025. Is there still a role for clindamycin and rifampicin in the treatment of hidradenitis suppurativa: A review of the literature. Clinical and Experimental Dermatology 50 (8), pp.1671-1676. (10.1093/ced/llaf160)
• Howells, L. et al., 2025. A qualitative interview study exploring patient views and experiences of treatment for hidradenitis suppurativa in the UK. British Journal of Dermatology 193 (1), pp.85-92. ljaf046. (10.1093/bjd/ljaf046)
• Kirby, J. S. et al., 2025. Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the Phase 3 BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa. British Journal of Dermatology 193 (1), pp.93-104. (10.1093/bjd/ljaf067)
• van Dalen, S. C. M. et al., 2025. Neutrophil extracellular traps are widely distributed across lesional and perilesional hidradenitis suppurativa skin, and elevated serum NET markers associate with moderate to severe HS disease. International Journal of Dermatology 64 (7), pp.1234-1241. (10.1111/ijd.17706)
• Shi, V. Y. et al., 2025. Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: pooled 48-week results from BE HEARD I&II. Dermatology and Therapy 15 , pp.2553-2570. (10.1007/s13555-025-01465-4)
• Gribaleva, E. et al., 2025. The UK-Irish Atopic eczema Systemic TherApy Register (A*STAR): Baseline characteristics of the cohort. British Journal of Dermatology 192 (5), pp.927-930. (10.1093/bjd/ljaf039)
• Ingram, J. R. 2025. Mechanistic insights into ruxolitinib cream for mild hidradenitis suppurativa. British Journal of Dermatology 192 (5), pp.789-790. ljaf019. (10.1093/bjd/ljaf019)
• Ingram, J. R. et al. 2025. Hidradenitis suppurativa symptom daily diary (HSSDD) and questionnaire (HSSQ): psychometric validation and interpretation threshold derivation using phase 3 study data. Dermatology and Therapy 15 , pp.1093-1111. (10.1007/s13555-025-01346-w)
• Zouboulis, C. C. et al., 2025. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment. Journal of the European Academy of Dermatology and Venereology 39 (5), pp.899-941. (10.1111/jdv.20472)
• Ingram, J. R. et al. 2025. Assessing long-term pain reduction with secukinumab in moderate to severe hidradenitis suppurativa: a post hoc analysis of the SUNSHINE and SUNRISE Phase 3 trials. Dermatology and Therapy (10.1007/s13555-025-01426-x)
• Hundal, S. et al., 2025. Cost-utility analysis of clinic-based deroofing versus local excision for hidradenitis suppurativa. Journal of The American Academy of Dermatology 92 (4), pp.773-780. (10.1016/j.jaad.2024.11.057)
• Pickles, T. and Ingram, J. R. 2025. Minimal important difference of pain numeric rating scale in patients with Hidradenitis suppurativa: results from THESEUS. British Journal of Dermatology 192 (4), pp.761-763. ljae486. (10.1093/bjd/ljae486)
• Shah, R. et al. 2025. Multiple sclerosis greatly impacts family members/partners: Evidence using the Family Reported Outcome Measure (FROM-16). Multiple Sclerosis Journal - Experimental, Translational and Clinical 11 (2) 20552173251338762. (10.1177/20552173251338762)
• Ingram, J. R. 2025. Hidradenitis suppurativa: BJD state-of-the-art review series. British Journal of Dermatology 192 (Supp_1), pp.i1-i2. (10.1093/bjd/ljae455)
• Shah, R. et al. 2025. Comparison of the impact of type 1 and type 2 diabetes on quality of life of families of patients: A UK cross‐sectional study. Diabetes, Obesity and Metabolism 27 (2), pp.652-662. (10.1111/dom.16058)
• Li, Y. H. et al., 2025. Comparing maximum and average numerical rating scale pain scores in hidradenitis suppurativa. Archives of Dermatological Research 317 (1) 496. (10.1007/s00403-025-03943-3)
• Ingram, J. R. et al. 2025. Implementation science to improve the diagnosis and management of hidradenitis suppurativa: HELyx study design overview. Dermatology and Therapy 15 (2), pp.463–472. (10.1007/s13555-025-01350-0)
• Ingram, J. R. et al. 2025. Hidradenitis suppurativa with and without draining tunnels: A real-world study characterizing differences in treatment and disease burden. Journal of the European Academy of Dermatology and Venereology (10.1111/jdv.20550)
• Sampath, A. J. et al., 2025. Standardized protocols for clinical and histopathological characterization of hidradenitis suppurativa tissue specimens. Journal of Investigative Dermatology 145 (1), pp.50-55. (10.1016/j.jid.2024.02.041)

2024

• Alexander, H. et al., 2024. A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register. British Journal of Dermatology 191 (6), pp.988-999. (10.1093/bjd/ljae287)
• Shah, R. et al. 2024. Dementia and its profound Impact on family members and partners. Alzheimer Disease & Associated Disorders 38 (4), pp.338-342. (10.1097/WAD.0000000000000647)
• Vyas, J. et al. 2024. A systematic review of 207 studies describing validation aspects of the dermatology life quality index. Acta Dermato-Venereologica 104 adv41120. (10.2340/actadv.v104.41120)
• Ingram, J. R. et al. 2024. Comprehensive codified algorithms to identify the underestimated burden of hidradenitis suppurativa in the United States. Dermatology and Therapy 14 , pp.2859–2876. (10.1007/s13555-024-01259-0)
• Johns, J. R. et al. 2024. The Dermatology Life Quality Index as the primary outcome in randomized clinical trials: a systematic review. British Journal of Dermatology 191 (4), pp.497-507. (10.1093/bjd/ljae228)
• Hernandez-Cordero, A. et al., 2024. A genome-wide meta-analysis of palmoplantar pustulosis implicates TH2 responses and cigarette smoking in disease pathogenesis. Journal of Allergy and Clinical Immunology 154 (3), pp.657-665. (10.1016/j.jaci.2024.05.015)
• Vyas, J. et al. 2024. The Dermatology Life Quality Index (DLQI) used as the benchmark in validation of 101 quality of life instruments: A systematic review. Journal of the European Academy of Dermatology and Venereology (10.1111/jdv.20321)
• Shah, R. et al. 2024. Measurement of the major ignored burden of multiple myeloma, pernicious anaemia and of other haematological conditions on partners and family members: A cross‐sectional study. European Journal of Haematology 113 (1), pp.117-126. (10.1111/ejh.14206)
• Bouazzi, D. et al., 2024. The Global Hidradenitis Suppurativa Atlas (GHiSA) methodology: Combining global proportions in a pooled analysis. Dermatology 240 (3), pp.369-375. (10.1159/000536389)
• Ahmed, A. et al., 2024. Methodological innovations and stakeholder involvement in core outcome sets for skin diseases: a survey of the C3 working groups. Archives of Dermatological Research 316 (4) 109. (10.1007/s00403-023-02812-1)
• Hasan, S. B. et al. 2024. Feasibility of daily pain measurement using text messages in Hidradenitis Suppurativa clinical trials; Data from THESEUS study. British Journal of Dermatology 190 (5), pp.775-777. ljae057. (10.1093/bjd/ljae057)
• Oyesiku, L. et al., 2024. Inclusive and equitable language for skin colour in the British Journal of Dermatology: acknowledging our past and laying the foundations to move forward. British Journal of Dermatology 190 (5), pp.605–607. (10.1093/bjd/ljae064)
• Ring, H. C. et al., 2024. Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: A Danish nationwide cohort study. British Journal of Dermatology 190 (5), pp.769-771. ljae042. (10.1093/bjd/ljae042)
• Kimball, A. B. et al., 2024. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. The Lancet 403 (10443), pp.2504-2519. (10.1016/S0140-6736(24)00101-6)
• Navarrete-Dechent, C. et al., 2024. The road to publication: Advice from journal editors [Letter from the Editor]. Journal of The American Academy of Dermatology 90 , pp.707-710. (10.1016/j.jaad.2023.11.038)
• Shah, R. et al. 2024. Mapping of family reported outcome measure (FROM-16) scores to EQ-5D: algorithm to calculate utility values. Quality of Life Research 33 , pp.1107-1119. (10.1007/s11136-023-03590-z)
• Wainman, H. E. et al., 2024. Global consensus process to establish a core data set for hidradenitis suppurativa registries. British Journal of Dermatology 190 (4), pp.510-518. (10.1093/bjd/ljad454)
• Garg, A. et al., 2024. Addressing high placebo response rates in randomized clinical trials for hidradenitis suppurativa. British Journal of Dermatology 190 (3), pp.427-429. (10.1093/bjd/ljad375)
• Ingram, J. R. et al. 2024. Treatment of hidradenitis suppurativa evaluation study (THESEUS): a prospective cohort study. British Journal of Dermatology 190 (3), pp.382-391. (10.1093/bjd/ljad388)
• Vyas, J. et al. 2024. A systematic review of 457 randomised controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries. British Journal of Dermatology 190 (3), pp.315-339. (10.1093/bjd/ljad079)
• Shah, R. et al. 2024. Responsiveness and minimal important change of the Family Reported Outcome Measure (FROM-16). Journal of Patient-Reported Outcomes 8 (1) 38. (10.1186/s41687-024-00703-1)
• Nadir, U. et al., 2024. Protocol of a scoping review of outcome domains in dermatology. BMJ Open 14 (2) e079632. (10.1136/bmjopen-2023-079632)
• Kimball, A. B. et al., 2024. Burden of hidradenitis suppurativa: a systematic literature review of patient reported outcomes. Dermatology and Therapy 14 , pp.83–98. (10.1007/s13555-023-01085-w)
• Ahmed, A. et al., 2024. Clinical relevance and uptake of core outcome sets in dermatology [Research letter]. Archives of Dermatological Research 316 (2) 78. (10.1007/s00403-023-02814-z)
• Ingram, J. R. et al. 2024. Treatment satisfaction in patients with hidradenitis suppurativa: A real-world survey from the EU5 and US. Dermatology (10.1159/000542343)

2023

• Ingram, J. R. et al. 2023. Treatment of hidradenitis suppurativa evaluation study: the THESEUS prospective cohort study. Health Technology Assessment 27 30. (10.3310/HWNM2189)
• Willems, D. et al., 2023. A discrete-choice experiment to elicit the treatment preferences of patients with hidradenitis suppurativa in the United States. Journal of Medical Economics (JME) 26 (1), pp.503-508. (10.1080/13696998.2023.2194804)
• Midgette, B. et al., 2023. Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project. British Journal of Dermatology 187 (6), pp.927-935. (10.1111/bjd.21798)
• Mastacouris, N. et al., 2023. Outcome measures for the evaluation of treatment response in hidradenitis suppurativa for clinical practice. JAMA Dermatology 159 (11), pp.1258-1266. (10.1001/jamadermatol.2023.3282)
• Maronese, C. A. , Ingram, J. R. and Marzano, A. V. 2023. Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa?. British Journal of Dermatology 189 (4), pp.467–468. (10.1093/bjd/ljad224)
• Ingram, J. R. et al. 2023. Electronic patient-reported outcomes in hidradenitis suppurativa: content validity and usability of the electronic hidradenitis suppurativa symptom daily diary, hidradenitis suppurativa symptom questionnaire and hidradenitis suppurativa quality of life questionnaire. Dermatology (10.1159/000534463)
• Leighton, P. et al., 2023. Research priorities in the management of Hidradenitis Suppurativa [Research Letter]. British Journal of Dermatology 189 (3), pp.343-345. (10.1093/bjd/ljad152)
• Williams, J. C. et al., 2023. Patient-reported influences on COVID-19 vaccine acceptance and hesitancy in people with hidradenitis suppurativa [Research Letter]. British Journal of Dermatology 189 (3), pp.351-353. (10.1093/bjd/ljad166)
• Ahmed, S. et al., 2023. Visualising complexity: embracing graphical abstracts in the BJD [Editorial]. British Journal of Dermatology 189 (2), pp.149-150. (10.1093/bjd/ljad181)
• Garg, A. et al., 2023. Factors associated with disease-specific life impact in patients with hidradenitis suppurativa: results from the Global VOICE project. British Journal of Dermatology 188 (6), pp.808-810. (10.1093/bjd/ljad069)
• Garg, A. et al., 2023. Validation of the Hidradenitis Suppurativa Investigator Global Assessment. JAMA Dermatology 159 (6), pp.606-612. (10.1001/jamadermatol.2023.0797)
• Shah, R. et al. 2023. Meaning of Family Reported Outcome Measure (FROM-16) severity score bands: a cross-sectional online study in the UK. BMJ Open 13 (3) e066168. (10.1136/bmjopen-2022-066168)
• Bosma, A. L. et al., 2023. Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types. JAAD International 10 , pp.14-24. (10.1016/j.jdin.2022.09.006)
• Ingram, J. R. 2023. A watershed moment for the BJD: Authors retain their article copyright. British Journal of Dermatology 188 (1), pp.1-2. (10.1093/bjd/ljac006)
• James, J. F. et al., 2023. Demographic gaps and requirements for participation: A systematic review of clinical trial designs in Hidradenitis Suppurativa. Dermatology 239 , pp.45-51. (10.1159/000526069)
• Wainman, H. E. , Lane, P. C. and Ingram, J. R. 2023. Hidradenitis suppurativa diagnosis and management in primary care: not just recurrent boils. British Journal of General Practice 73 (726), pp.43-45. (10.3399/bjgp23X731733)
• Willems, D. et al., 2023. Patient preferences in the management of hidradenitis suppurativa: results of a multinational discrete choice experiment in Europe. The Patient - Patient-Centered Outcomes Research 16 (2), pp.153-164. (10.1007/s40271-022-00614-7)

2022

• Williams, J. C. et al., 2022. Biologic therapy is not associated with increased covid-19 severity in patients with hidradenitis suppurativa: updated findings from the global hidradenitis suppurativa covid-19 registry. Dermatology (10.1159/000527401)
• Hasan, S. et al. 2022. Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: A scoping review to inform pain measurement in hidradenitis suppurativa. British Journal of Dermatology 187 (6), pp.846-854. (10.1111/bjd.21821)
• Ring, H. C. et al., 2022. The road to biologics in patients with hidradenitis suppurativa - a nationwide drug utilization study. British Journal of Dermatology 187 (4), pp.523-530. (10.1111/bjd.21673)
• McCluskey, D. et al., 2022. Single-cell analysis implicates Th17-to-Th2 cell plasticity in the pathogenesis of palmoplantar pustulosis. Journal of Allergy and Clinical Immunology 150 (4), pp.882-893. (10.1016/j.jaci.2022.04.027)
• van Straalen, K. R. et al., 2022. New treatments and new assessment instruments for hidradenitis suppurativa. Experimental Dermatology 31 (s1), pp.33-39. (10.1111/exd.14609)
• Garg, A. et al., 2022. Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials. British Journal of Dermatology 187 (2), pp.203-210. (10.1111/bjd.21236)
• Garg, A. et al., 2022. Shifting focus from “what we do” to the “impact of what we do”: Application of outcome measures to routine clinical care in dermatology. Journal of The American Academy of Dermatology 87 , pp.83-84. (10.1016/j.jaad.2022.04.042)
• Yiu, Z. Z. N. et al., 2022. Checking for update…living systematic reviews and clinical practice guidelines in the BJD. British Journal of Dermatology 186 (5), pp.761-762. (10.1111/bjd.20896)
• Bates, J. et al., 2022. Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): protocol for a prospective cohort study. BMJ Open 12 (4) e060815. (10.1136/bmjopen-2022-060815)
• Ingram, J. et al. 2022. Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US. Journal of the European Academy of Dermatology and Venereology 36 (9), pp.1597-1605. (10.1111/jdv.18163)
• Maghfour, J. et al., 2022. From the Cochrane Library: interventions for hidradenitis suppurativa. JMIR Dermatology 5 (1) e29966. (10.2196/29966)
• van Huizen, A. M. et al., 2022. International eDelphi study to reach consensus on the methotrexate dosing regimen in patients with psoriasis. JAMA Dermatology 158 (5), pp.561-572. (10.1001/jamadermatol.2022.0434)
• Cro, S. et al., 2022. Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two staged, adaptive placebo controlled trial (APRICOT). British Journal of Dermatology 186 (2), pp.245-256. (10.1111/bjd.20653)
• Tatovic, D. et al. 2022. Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in Type 1 diabetes. Immunotherapy Advances 2 (1) ltac002. (10.1093/immadv/ltac002)
• Howes, R. et al., 2022. The surgical management of hidradenitis suppurativa in the United Kingdom: a national survey of care pathways informing the THESEUS study. Journal of Plastic, Reconstructive and Aesthetic Surgery 75 (1), pp.240-247. (10.1016/j.bjps.2021.08.038)
• Naik, H. B. et al., 2022. Biologic therapy is not associated with increased COVID-19 severity in Hidradenitis Suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry. Journal of The American Academy of Dermatology 86 (1), pp.249-252. (10.1016/j.jaad.2021.09.016)

2021

• Guckian, J. et al., 2021. Dermatology is finally talking about race. British Journal of Dermatology 185 (5), pp.875-876. (10.1111/bjd.20599)
• Howells, L. et al., 2021. Thematic synthesis of the experiences of people with Hidradenitis Suppurativa: a systematic review. British Journal of Dermatology 185 (5), pp.921-934. (10.1111/bjd.20523)
• Burgin, S. et al., 2021. The essential role of dermatology publications in enhancing professional diversity, equity, and inclusion. Journal of Cosmetic Dermatology 20 (10), pp.3060-3061. (10.1111/jocd.14435)
• Drucker, A. M. and Ingram, J. R. 2021. Widening the tightrope: new abstract guidelines for BJD authors. British Journal of Dermatology 185 (4), pp.687-688. (10.1111/bjd.20498)
• Burgin, S. et al., 2021. The essential role of dermatology publications in enhancing professional diversity, equity and inclusion. British Journal of Dermatology 185 (3), pp.473-474. (10.1111/bjd.20473)
• Hasan, S. B. et al. 2021. British Association of Dermatologists (BAD) national clinical audit on the management of Hidradenitis Suppurativa (HS) in the UK. Clinical and Experimental Dermatology 46 (6), pp.1023-1027. (10.1111/ced.14598)
• Collier, F. et al., 2021. Primary care management of hidradenitis suppurativa: a cross-sectional survey of UK GPs. British Journal of General Practice Open 0051. (10.3399/BJGPO.2021.0051)
• Veysey, E. C. et al., 2021. Core outcome set implementation supported by the BJD. British Journal of Dermatology 184 (6), pp.987-989. (10.1111/bjd.20050)
• Wall, D. et al., 2021. Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. Clinics in Dermatology 39 (3), pp.467-478. (10.1016/j.clindermatol.2021.01.018)
• Sach, T. et al., 2021. An economic evaluation of the randomised controlled trial of topical corticosteroid and home‐based narrowband UVB for active and limited vitiligo (The HI‐Light Trial). British Journal of Dermatology 184 (5), pp.840-848. (10.1111/bjd.19554)
• Thomas, K. et al., 2021. Randomised controlled trial of topical corticosteroid and home-based narrowband UVB for active and limited vitiligo - results of the HI-Light Vitiligo trial. British Journal of Dermatology 184 (5), pp.828-839. (10.1111/bjd.19592)
• Shah, R. et al. 2021. Measuring the impact of COVID-19 on the quality of life of the survivors, partners and family members: a cross-sectional international online survey. BMJ Open 11 (5) e047680. (10.1136/bmjopen-2020-047680)
• Frew, J. W. et al., 2021. Global harmonization of morphological definitions in hidradenitis suppurativa for a proposed glossary. JAMA Dermatology 157 (4), pp.449-455. (10.1001/jamadermatol.2020.5467)
• Jedrzejczak, M. J. et al., 2021. Expert knowledge, attitudes, and practices in management of hidradenitis suppurativa pain. JAMA Dermatology 157 (4), pp.464-466. (10.1001/jamadermatol.2020.5857)
• Kirby, J. .. et al., 2021. Validation of patient global item for quality of life impact on Hidradenitis suppurativa. British Journal of Dermatology 184 (4), pp.681-687. (10.1111/bjd.19344)
• Ingram, J. and Ahluwalia, A. 2021. The pharmacology of itch. British Journal of Dermatology 184 (1), pp.e1-e2. (10.1111/bjd.18525)

2020

• Altayeb, A. et al., 2020. Two cases of skin manifestations prior to the onset of COVID-19 respiratory symptoms. International Journal of Dermatology 59 (12), pp.1541-1542. (10.1111/ijd.15247)
• Ingram, J. R. 2020. The epidemiology of hidradenitis suppurativa. British Journal of Dermatology 183 (6), pp.990-998. (10.1111/bjd.19435)
• Soriano, L. F. et al., 2020. Effectiveness of a stop smoking service in reducing cigarette smoking in patients referred from an NHS dermatology centre. British Journal of Dermatology 183 (6), pp.1119-1121. (10.1111/bjd.19378)
• Zouboulis, C. C. et al., 2020. What causes hidradenitis suppurativa ? - 15 years after. Experimental Dermatology 29 (12), pp.1154-1170. (10.1111/exd.14214)
• Jung, F. et al., 2020. Systematic review of efficacies and adverse effects of treatments for Pityriasis lichenoides. British Journal of Dermatology 183 (6), pp.1026-1032. (10.1111/bjd.18977)
• Hasan, S. and Ingram, J. 2020. What has changed in the UK management of hidradenitis suppurativa from 2014 to 2019?. British Journal of Dermatology 183 (5), pp.973-975. (10.1111/bjd.19302)
• Ingram, J. R. et al. 2020. The prevalence of hidradenitis suppurativa is shown by the Secure Anonymised Information Linkage (SAIL) Databank to be one per cent of the population of Wales. British Journal of Dermatology 183 (5), pp.950-952. (10.1111/bjd.19210)
• Millington, A. et al., 2020. Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT. Health Technology Assessment 24 (64), pp.1-183. (10.3310/hta24640)
• Naik, H. B. et al., 2020. Global hidradenitis suppurativa COVID-19 registry: a registry to inform data-driven management practices. British Journal of Dermatology 183 (4), pp.780-781. (10.1111/bjd.19345)
• Vergnano, M. et al., 2020. Loss-of-function myeloperoxidase mutations are associated with increased neutrophil counts and pustular skin disease. American Journal of Human Genetics 107 (3), pp.539-543. (10.1016/j.ajhg.2020.06.020)
• Ahmed, S. et al., 2020. Consent for publication: why it matters now more than ever. British Journal of Dermatology 183 (3), pp.409-410. (10.1111/bjd.19320)
• Kirby, J. et al., 2020. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. British Journal of Dermatology 183 (2), pp.340-348. (10.1111/bjd.18692)
• Zouboulis, C. C. et al., 2020. Endpoints of clinical trials for Hidradenitis Suppurativa: proceedings of a round-table session. Experimental Dermatology 29 (S1), pp.67-72. (10.1111/exd.14123)
• Zuuren, E. J. et al., 2020. Publication of national dermatology guidelines as a research letter in the BJD : can less ever be enough?. British Journal of Dermatology 182 (6), pp.1319-1320. (10.1111/bjd.18952)
• Freeman, E. E. et al., 2020. International collaboration and rapid harmonization across dermatologic COVID-19 registries. Journal of The American Academy of Dermatology (10.1016/j.jaad.2020.06.050)
• Hasan, S. , Ali, F. and Ingram, J. 2020. Cholinergic pruritus responding to Omalizumab. Clinical and Experimental Dermatology 45 (2), pp.264-266. (10.1111/ced.14052)
• Garg, A. et al., 2020. Evaluating patients' unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. Journal of The American Academy of Dermatology 82 (2)(10.1016/j.jaad.2019.06.1301)

2019

• Frew, J. et al., 2019. Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies. British Journal of Dermatology 181 (6)(10.1111/bjd.18309)
• Wernham, A. et al., 2019. A five-year review of quality of reporting of research using clinician surveys in high-ranked dermatology journals. British Journal of Dermatology 181 (4), pp.845-847. (10.1111/bjd.17942)
• Ingram, J. 2019. BJD: onwards and upwards. British Journal of Dermatology 181 (1), pp.1-2. (10.1111/bjd.18034)
• Prinsen, C. A. et al., 2019. Navigating the landscape of core outcome set development in dermatology. Journal of the American Academy of Dermatology 81 (1), pp.297-305. (10.1016/j.jaad.2019.03.009)
• Ingram, J. et al. 2019. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. British Journal of Dermatology 180 (5), pp.1009-1017. (10.1111/bjd.17537)
• Ho, B. et al., 2019. A survey of the treatment and management of patients with severe chronic spontaneous urticaria. Clinical and Experimental Dermatology 44 (3), pp.353-355. (10.1111/ced.13778)
• Scrivens, L. , Jacquet, L. and Ingram, J. 2019. BJD Medical Student Editors: reaching out to undergraduates in a rapidly evolving world of digital dermatology publishing. British Journal of Dermatology 180 (2), pp.251-252. (10.1111/bjd.17397)

2018

• Callander, J. et al. 2018. Treatment of clinically amyopathic dermatomyositis in adults: a systematic review. British Journal of Dermatology 179 (6), pp.1248-1255. (10.1111/bjd.14726)
• Thorlacius, L. et al., 2018. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. British Journal of Dermatology 179 (3), pp.642-650. (10.1111/bjd.16672)
• Garcia-Doval, I. et al., 2018. Optimizing case reports and case series: guidance on how to improve quality. British Journal of Dermatology 178 (6), pp.1257-1262. (10.1111/bjd.16467)
• Wernham, A. , Ingram, J. R. and Matin, R. 2018. Clinician surveys: time to make better use of this valuable resource for dermatologists. British Journal of Dermatology 178 (6), pp.1466-1467. (10.1111/bjd.16444)
• Ingram, J. R. 2018. Atopic eczema and cardiovascular disease. BMJ 361 k2064. (10.1136/bmj.k2064)
• Ingram, J. R. et al. 2018. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. British Journal of Dermatology 178 (4), pp.917-924. (10.1111/bjd.16101)
• Thorlacius, L. et al., 2018. Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II. British Journal of Dermatology 178 (3), pp.715-721. (10.1111/bjd.16093)
• George, S. and Ingram, J. 2018. BJD support for dermatology journal clubs: nurturing Sir William Osler's legacy. British Journal of Dermatology 178 (2), pp.313-314. (10.1111/bjd.16164)
• Ingram, J. et al. 2018. Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study). Diabetic Medicine 35 (2), pp.255-261. (10.1111/dme.13431)

2017

• Sbidian, E. et al., 2017. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database of Systematic Reviews (12) CD011535. (10.1002/14651858.CD011535.pub2)
• Garcia-Doval, I. et al., 2017. Systematic reviews: let's keep them trustworthy. British Journal of Dermatology 177 (4), pp.888-889. (10.1111/bjd.15826)
• Callander, J. et al., 2017. How to write a Critically Appraised Topic: evidence to underpin routine clinical practice. British Journal of Dermatology 177 (4), pp.1007-1013. (10.1111/bjd.15873)
• Tang, H. K. C. et al., 2017. Delayed and localized pemphigus vulgaris after breast cancer radiotherapy. The Breast Journal 23 (6), pp.747-749. (10.1111/tbj.12910)
• Ingram, J. R. 2017. Interventions for hidradenitis suppurativa. JAMA Dermatology 153 (5), pp.458-459. (10.1001/jamadermatol.2017.0432)
• Williams, H. C. et al., 2017. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 389 (10079), pp.1630-1638. (10.1016/S0140-6736(17)30560-3)
• Ingram, J. R. and Burton, T. 2017. NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?. British Journal of Dermatology 176 (2), pp.281-282. (10.1111/bjd.15255)
• Thorlacius, L. et al., 2017. Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes. BMJ Open 7 (2) e014733. (10.1136/bmjopen-2016-014733)
• Tappenden, P. et al., 2017. Adalimumab for treating moderate-to-severe hidradenitis suppurativa: an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics 35 (8), pp.805-815. (10.1007/s40273-017-0488-2)
• Ingram, J. R. and Anstey, A. 2017. The evolution of clinical guidelines for dermatologists: GRADE, AGREE and occasionally consensus by experts. British Journal of Dermatology 176 (1), pp.3-4. (10.1111/bjd.15178)
• Mukkanna, K. S. , Stone, N. M. and Ingram, J. R. 2017. Para-phenylenediamine allergy: current perspectives on diagnosis and management. Journal of Asthma and Allergy 10 , pp.9-15. (10.2147/JAA.S90265)
• Atwan, A. et al., 2017. Dermatology life quality index (DLQI) as a psoriasis referral triage tool. British Journal of Dermatology 177 (4), pp.e136-e137. (10.1111/bjd.15446)
• Zouboulis, C. C. et al., 2017. Development and validation of IHS4, a novel dynamic scoring system to assess hidradenitis suppurativa/acne inversa severity. British Journal of Dermatology 177 (5), pp.1401-1409. (10.1111/bjd.15748)

2016

• Thomas, K. S. et al., 2016. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study. Journal of the American Academy of Dermatology 75 (5), pp.940-949. (10.1016/j.jaad.2016.06.016)
• Daxhelet, M. et al., 2016. Establishment of a European Registry for hidradenitis suppurativa/acne inversa by using an open source software. Journal of the European Academy of Dermatology and Venereology 30 (8), pp.1424-1426. (10.1111/jdv.13267)
• Ingram, J. R. et al. 2016. Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. British Journal of Dermatology 174 (5), pp.970-978. (10.1111/bjd.14418)
• Atwan, A. et al., 2016. Oral fumaric acid esters for psoriasis: abridged Cochrane systematic review including GRADE assessments. British Journal of Dermatology 175 (5), pp.873-881. (10.1111/bjd.14676)
• Ingram, J. R. , Hadjieconomou, S. and Piguet, V. 2016. Development of core outcome sets in hidradenitis suppurativa:a systematic review of outcome measure instruments to inform the process. British Journal of Dermatology 175 (2), pp.263-272. (10.1111/bjd.14475)
• Ingram, J. R. 2016. Hidradenitis suppurativa: an update. Clinical Medicine 16 (1), pp.70-73. (10.7861/clinmedicine.16-1-70)
• Ingram, J. R. 2016. The genetics of Hidradenitis Suppurativa. Dermatologic Clinics 34 (1), pp.23-28. (10.1016/j.det.2015.07.002)

2015

• Ingram, J. R. and Paul, C. 2015. Academic mentorship in dermatology. British Journal of Dermatology 173 (5), pp.1113-1114. (10.1111/bjd.14197)
• Ingram, J. R. and McPhee, M. 2015. Management of hidradenitis suppurativa: a UK survey of current practice. British Journal of Dermatology 173 (4), pp.1070-1072. (10.1111/bjd.13866)
• Ingram, J. R. et al. 2015. Interventions for hidradenitis suppurativa. Cochrane Database of Systematic Reviews (10) CD010081. (10.1002/14651858.CD010081.pub2)
• Atwan, A. et al., 2015. Oral fumaric acid esters for psoriasis. Cochrane Database of Systematic Reviews (8) CD010497. (10.1002/14651858.CD010497.pub2)
• George, S. and Ingram, J. R. 2015. Introducing cover image as a new category of publication in the BJD. British Journal of Dermatology 173 (2), pp.315-315. (10.1111/bjd.13964)
• Ormerod, A. D. et al., 2015. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 350 h2958. (10.1136/bmj.h2958)
• Chalmers, J. R. et al., 2015. A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0·5 mg kg-1 daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial. British Journal of Dermatology 173 (1), pp.227-234. (10.1111/bjd.13729)
• Nankervis, H. et al., 2015. Validation of the global resource of eczema trials (GREAT database). BMC Dermatology 15 (4)(10.1186/s12895-015-0024-z)

2014

• Ingram, J. 2014. The quest for excellence (part 2): reviewing a clinical trial for the British Journal of Dermatology. British Journal of Dermatology 171 (6), pp.1277-1278. (10.1111/bjd.13445)
• Ingram, J. 2014. The quest for excellence (part 1): becoming a reviewer for the British Journal of Dermatology. British Journal of Dermatology 171 (5), pp.921-922. (10.1111/bjd.13404)
• Warburton, K. L. et al., 2014. Management of morphoea: results of a national survey of UK clinicians. British Journal of Dermatology 171 (5), pp.1243-1245. (10.1111/bjd.13062)
• Ingram, J. R. et al. 2014. The Hidradenitis Suppurativa Priority Setting Partnership. British Journal of Dermatology 171 (6), pp.1422-1427. (10.1111/bjd.13163)
• Chin, M. F. et al., 2014. Patient-reported outcome measure of pain experienced during administration of local anaesthesia in cutaneous surgery: a tool for appraisal [Abstract]. British Journal of Dermatology 171 , pp.80-80.
• Ingram, J. 2014. Hidradenitis suppurativa outcome measures and treatment goals. British Journal of Dermatology 171 (6), pp.1293-1294. (10.1111/bjd.13396)
• Ingram, J. R. et al. 2014. A Cochrane Systematic Review of interventions for Hidradenitis Suppurativa. Journal of Investigative Dermatology 134 , pp.S40-S40.
• Ingram, J. R. , Hughes, T. M. and Stone, N. M. 2014. Potential danger of hair dyes marketed as free from para-phenylenediamine. International Journal of Dermatology 53 (4), pp.e257-e258. (10.1111/ijd.12296)

2013

• Ingram, J. R. , Anderson, E. J. and Pugsley, L. 2013. Difficulty giving feedback on underperformance undermines the educational value of multi-source feedback. Medical Teacher 35 (10), pp.838-846. (10.3109/0142159X.2013.804910)
• Burr, M. L. et al. 2013. The natural history of eczema from birth to adult life: a cohort study. British Journal of Dermatology 168 (6), pp.1339-1342. (10.1111/bjd.12216)
• Ingram, J. R. 2013. Interpreting outcome measures and defining treatment success. British Journal of Dermatology 169 (6), pp.1177-1178. (10.1111/bjd.12709)
• Ingram, J. R. et al. 2013. Segmental cherry angiomas associated with extragenital lichen sclerosus: a report of two cases. Clinical and Experimental Dermatology 38 (4), pp.386-389. (10.1111/j.1365-2230.2012.04479.x)
• Ingram, J. R. and Piguet, V. 2013. Phenotypic heterogeneity in Hidradenitis Suppurativa (Acne Inversa): classification is an essential step toward personalized therapy. Journal of Investigative Dermatology 133 (6), pp.1453-1456. (10.1038/jid.2012.476)
• Ingram, J. R. et al. 2013. Absence of pathogenic γ-secretase mutations in a South Wales cohort of familial and sporadic hidradenitis suppurativa (acne inversa). British Journal Of Dermatology 168 (4), pp.874-876. (10.1111/bjd.12048)
• Matin, R. N. et al., 2013. The UK Dermatology Clinical Trials Network Trainee Group: developing evidence-based practice and research engagement among dermatology trainees. British Journal of Dermatology 169 , pp.35-35.
• Ponnambath, N. et al., 2013. Practical experience of biological treatment of very severe psoriasis: a retrospective case-cohort study of patients with a baseline Psoriasis Area and Severity Index score greater than 20 [Abstract]. British Journal of Dermatology 169 (s1), pp.41-41. (10.1111/bjd.12306)

2012

• Craig, F. F. et al., 2012. UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial. Trials 13 (1), pp.51. (10.1186/1745-6215-13-51)
• Enk, A. , Ingram, J. R. and Piguet, V. 2012. Future leaders: mentor investment in young investigators. Journal of Investigative Dermatology 132 (8), pp.1943-1944. (10.1038/jid.2012.55)
• Hodges, N. , Anstey, A. and Ingram, J. R. 2012. Fumaric acid esters for psoriasis: patient perceptions of an unlicensed medication [Abstract]. Journal of the American Academy of Dermatology 66 (4), pp.AB193-AB193. (10.1016/j.jaad.2011.11.809)
• Ingram, J. R. , Anstey, A. V. and Piguet, V. 2012. Combination treatment with a tumour necrosis factor antagonist and an oral retinoid: efficacy in severe acral psoriasis? [Letter]. British Journal Of Dermatology 167 (4), pp.949-951. (10.1111/j.1365-2133.2012.10983.x)
• Ingram, J. R. et al. 2012. A bum deal from wooden toilet seats: reemergence of allergic contact dermatitis. Dermatitis 23 (5), pp.244-245.

2011

• Ali, F. et al. 2011. X-linked dominant protoporphyria due to a novel mutation in ALAS2: a case report [Abstract]. British Journal of Dermatology 164 (5), pp.1167-1167. (10.1111/j.1365-2133.2011.10357.x)
• Ingram, J. R. et al. 2011. An unusual complication of jaundice [Abstract]. British Journal of Dermatology 164 (5), pp.1168-1168. (10.1111/j.1365-2133.2011.10357.x)
• Ingram, J. R. 2011. The aetiology of acne inversa: an evolving story. British Journal of Dermatology 165 (2), pp.231-232. (10.1111/j.1365-2133.2011.10459.x)
• Ingram, J. R. et al. 2011. Absence of pathogenic gamma-secretase mutations in familial and sporadic acne inversa in a European population [Abstract]. Journal of Investigative Dermatology 131 (Supp 2), pp.S68-S68. (10.1038/jid.2011.214)

2010

• Ingram, J. R. , Grindlay, D. J. C. and Williams, H. C. 2010. Management of "acne vulgaris": an evidence-based update. Clinical and Experimental Dermatology 35 (4), pp.351-354. (10.1111/j.1365-2230.2009.03683.x)
• Ingram, J. R. , Grindlay, D. J. C. and Williams, H. C. 2010. Problems in the reporting of acne clinical trials: a spot check from the 2009 Annual Evidence Update on Acne Vulgaris. Trials 11 77. (10.1186%2F1745-6215-11-77)
• Paulden, M. et al., 2010. Alitretinoin for the treatment of severe chronic hand eczema. Health Technology Assessment 14 , pp.39-46. (10.3310/hta14Suppl1/06)
• Rodgers, M. et al., 2010. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal. Pharmacoeconomics 28 (5), pp.351-362. (10.2165/11532160-000000000-00000.)

2009

• Batchelor, J. M. , Ingram, J. R. and Williams, H. 2009. Adalimumab vs Methotrexate for the treatment of chronic plaque psoriasis. Archives of Dermatology 145 (6), pp.704-706. (10.1001/archdermatol.2009.104)
• Ingram, J. R. 2009. Nicotine: does it have a role in the treatment of skin disease?. Postgraduate Medical Journal 85 (1002), pp.196-201. (10.1136/pgmj.2008.073577.)
• Ingram, J. R. , Batchelor, J. M. and Williams, H. C. 2009. Alitretinoin as a potential advance in the management of severe chronic hand eczema. Archives of Dermatology 145 (3), pp.314-315. (10.1001/archdermatol.2008.608.)
• Ingram, J. R. , Griffiths, A. P. and Roberts, D. L. 2009. All patients with sebaceous gland neoplasms should be screened for Muir-Torre syndrome. Clinical and Experimental Dermatology 34 (2), pp.264-266. (10.1111/j.1365-2230.2008.02830.x)
• Ingram, J. R. , Martin, J. A. and Finlay, A. Y. 2009. Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis. American Journal of Clinical Dermatology 10 (4), pp.229-237. (10.2165/00128071-200910040-00003.)

2008

• Ingram, J. R. , Hughes, M. and Stone, N. M. 2008. Occupational allergic contact dermatitis to polyfunctional aziridine crosslinker in a 'tufter'. Contact Dermatitis 58 (3), pp.172-U7. (10.1111/j.1600-0536.2007.01216.x)
• Ingram, J. R. et al. 2008. Nicotine enemas for active Crohn's colitis: an open pilot study. Gastroenterology Research and Practice 2008 237185.

2005

• Ingram, J. R. et al. 2005. Plasma fibrinogen in ulcerative colitis: The effect of disease activity and nicotine therapy in a randomised controlled trial. Digestive and Liver Disease 37 (11), pp.832-837. (10.1016/j.dld.2005.05.010)
• Ingram, J. R. et al. 2005. A randomized trial of nicotine enemas for active ulcerative colitis. Clinical Gastroenterology and Hepatology 3 (11), pp.1107-1114. (10.1016/S1542-3565(05)00849-9)
• Thomas, G. A. O. , Rhodes, J. and Ingram, J. R. 2005. Mechanisms of disease: nicotine - a review of its actions in the context of gastrointestinal disease. Nature Clinical Practice Gastroenterology & Hepatology 2 (11), pp.536-544. (10.1038/ncpgasthep0316)
• Ingram, J. R. et al. 2005. Preliminary observations of oral nicotine therapy for inflammatory bowel disease: An open-label phase I-II study of tolerance. Inflammatory Bowel Diseases 11 (12), pp.1092-1096.